Publications by authors named "Philip A Thompson"

Claim this Profile
R
Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.
Stephen P Mulligan, Philip A Thompson, Joel Wight, Mary Ann Anderson, Sasanka M Handunnetti

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.
Sasanka M Handunnetti, Amit Khot, Piers Blombery, Kate Burbury, Philip A Thompson

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Balancing gains and pains: infections in the bispecific era.
Nalian H Ibrahim, Philip A Thompson, Benjamin W Teh

Leuk Lymphoma· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.
Edward R Scheffer Cliff, Thomas E Lew, Florian Simon, Talal Hilal, Mary Ann Anderson, Philip A Thompson

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in the Understanding of Richter Transformation.
Philip A Thompson, Erin M Parry

Hematol Oncol Clin North Am· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression.
Shady I Tantawy, Burcu Aslan, Ganiraju Manyam, LaKesla R Iles, Natalia Timofeeva, Philip A Thompson

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era.
Cecelia R Miller, Ying Huang, John N Allan, Seema A Bhat, David Bond, Meghan C Thompson, Philip A Thompson

Am J Hematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single-institution study of allograft outcomes for chronic lymphocytic leukaemia over 20 years.
Rory Bennett, Thomas Frawley, Philip A Thompson, Ashley Whitechurch, Amit Khot

Intern Med J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia.
Brian T Grainger, Philip A Thompson, Chan Y Cheah

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.
Adam S Kittai, Monia Marchetti, Othman Al-Sawaf, Ohad Benjamini, Alexey V Danilov, Philip A Thompson

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artificial Intelligence Assessment of Chest Radiographs for COVID-19.
Koji Sasaki, Guillermo Garcia-Manero, Masayuki Nigo, Elias Jabbour, Farhad Ravandi, Philip A Thompson

Clin Lymphoma Myeloma Leuk· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL.
Adam S Kittai, Ying Huang, Sarah Miller, John N Allan, Seema A Bhat, Meghan C Thompson, Philip A Thompson

Blood Cancer J· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.
William G Wierda, Nirav N Shah, Chan Y Cheah, David Lewis, Marc S Hoffmann, Philip A Thompson

Lancet Haematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Sasanka M Handunnetti, Mary Ann Anderson, Kate Burbury, Philip A Thompson, Glenda Burke

Blood· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ending endless follow-up for low-risk CLL?
Philip A Thompson

Blood Adv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
Adam S Kittai, David Bond, Ying Huang, Seema A Bhat, Emily Blyth, Philip A Thompson

J Clin Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BTK inhibitors in CLL: second-generation drugs and beyond.
Constantine Tam, Philip A Thompson

Blood Adv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pairing obinutuzumab with venetoclax in relapsed CLL.
Kerry A Rogers, Philip A Thompson

Leuk Lymphoma· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Paul J Hampel, Mahesh Swaminathan, Kerry A Rogers, Erin M Parry, Jan A Burger, Philip A Thompson

Blood Adv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.
Thomas E Lew, Rory Bennett, Victor S Lin, Ashley Whitechurch, Sasanka M Handunnetti, Philip A Thompson

Blood Adv· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
Philip A Thompson, Alexandre Bazinet, William G Wierda, Constantine S Tam, Susan M O'Brien

Blood· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation.
Laura M Roccograndi, Alexandra R Lovell, Alessandra Ferrajoli, Philip A Thompson, Jan A Burger

Leuk Lymphoma· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.
Philip A Thompson, Michael J Keating, Alessandra Ferrajoli, Nitin Jain, Christine B Peterson

Leukemia· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma.
Siba El Hussein, L Jeffrey Medeiros, Kirill A Lyapichev, Hong Fang, Fatima Zahra Jelloul, Philip A Thompson

Pathology· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders.
Philip A Thompson, Constantine S Tam

Blood· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis